FLJ11506 inhibitors encompass a distinct class of chemical compounds that have been identified for their specific action of obstructing the functional activity of the FLJ11506 protein. This protein, encoded by a gene of the same moniker, plays a pivotal role in a particular cellular pathway that is critical for the regulation of certain biological processes. The inhibitors function by directly interacting with the FLJ11506 protein or by indirectly affecting the signaling pathways that FLJ11506 is known to be involved in. The direct inhibitors typically bind to the active site or to an allosteric site of the protein, leading to a conformational change that reduces the protein's activity. On the other hand, indirect inhibitors might act on upstream or downstream elements in the pathway, culminating in the suppression of FLJ11506 activity. These chemical compounds are characterized by their high specificity and the precision with which they target the mechanisms of action of FLJ11506, making them a focal point for studies into the modulation of the associated biological processes.
The mode of action of FLJ11506 inhibitors can be quite diverse, reflecting the complexity of the signaling networks in which the FLJ11506 protein operates. Some inhibitors may prevent the phosphorylation of FLJ11506, which is often a prerequisite for its activation. Others might inhibit the expression of FLJ11506 by interfering with the transcription factors or the transcriptional machinery required for its gene expression. Additionally, certain compounds may impede the protein's interaction with its co-factors or substrates, thereby inhibiting its enzymatic activity or the propagation of a signaling cascade. The intricate nature of these interactions underscores the specificity of FLJ11506 inhibitors and highlights the sophisticated level of control they exert over the protein's activity. Importantly, the exploration of these inhibitors is entirely focused on understanding the fundamental biochemical and cellular processes adhering strictly to the scientific investigation of protein function modulation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor. FLJ11506 is assumed to be associated with EGFR signaling. By inhibiting EGFR, erlotinib would reduce the downstream signaling cascades that could include the functional activity of FLJ11506. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. If FLJ11506 activity is linked to mTOR signaling pathways, inhibiting mTOR with rapamycin would decrease the functional activity of FLJ11506 due to a reduction in the signaling events necessary for its activation. | ||||||
Triciribine | 35943-35-2 | sc-200661 sc-200661A | 1 mg 5 mg | $104.00 $141.00 | 14 | |
Triciribine is an AKT inhibitor, which blocks the PI3K/AKT/mTOR pathway. If FLJ11506 functions downstream of AKT, its activity would be decreased by preventing AKT-mediated signaling events. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor which would block the PI3K/AKT pathway. If FLJ11506 is involved in this pathway, its activity would be reduced by inhibiting upstream PI3K signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a RAF inhibitor that also affects the MAPK/ERK pathway. If FLJ11506 is regulated by MAPK/ERK signaling, then inhibiting this pathway would result in a decrease in FLJ11506 activity. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor targeting BCR-ABL, c-KIT, and PDGFR. If FLJ11506 is part of a pathway involving these kinases, its activity would be decreased due to inhibition of upstream signaling. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is another EGFR inhibitor. Similar to erlotinib, if FLJ11506 is part of the EGFR signaling cascade, gefitinib would decrease the functional activity of FLJ11506 by blocking EGFR. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a SRC-family tyrosine kinase inhibitor. If FLJ11506 is activated downstream of SRC kinases, dasatinib would reduce FLJ11506 activity by inhibiting these kinases. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
WZ4002 is a selective EGFR inhibitor that targets T790M resistance mutations. If FLJ11506 activity is associated with EGFR, particularly mutated forms, inhibition by WZ4002 would decrease FLJ11506 activity. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is a dual mTORC1 and mTORC2 inhibitor. If FLJ11506 is a part of the mTOR signaling pathway, AZD8055 would lead to decreased FLJ11506 function by inhibiting both mTOR complexes. | ||||||